Hcy levels in insulin resistance and diabetes

M. Brosnan,J. Brosnan,E. Wijekoon

Abstract:An increase in the plasma level of Hcy (homocysteine), an intermediate in the catabolism of methionine, has been identified as a risk factor for many diseases including CVD (cardiovascular disease). CVD is the major cause of death in patients with diabetes mellitus. Therefore the study of Hcy metabolism in diabetes mellitus has been a major focus of current research. Studies conducted in our laboratory were able to show that in both Type 1 and Type 2 diabetes with no renal complications, the plasma Hcy levels were lower than in controls. In Type 1 diabetes, increased activities of the trans-sulfuration enzymes were the major cause for the reduction in plasma Hcy. In Type 2 diabetes, BHMT (betaine:homocysteine methyltransferase) was also observed to play a major role in the increased catabolism of Hcy in addition to the trans-sulfuration enzymes. We were also able to demonstrate the direct effect of insulin and the counter-regulatory hormones on the regulation of cystathionine β-synthase and BHMT, which accounts for the changes in the activities of these two enzymes seen in diabetes mellitus. Background Since the observation, by McCully [1], of severe arteriosclerotic lesions in children with HHcy (hyperhomocysteinaemia) and homocysteinuria, a large number of studies have linked moderate HHcy to atherosclerotic disease. Mean plasma tHcy [total Hcy (homocysteine)] was found to be significantly higher both in male and female patients with coronary artery disease compared with controls with angiographically normal coronary arteries [2]. An increase in plasma Hcy of only 12% greater than the upper limit of normal was shown to be associated with an increase by 3.4fold in the risk of myocardial infarction [3]. After adjusting for possible confounders, Arnesen et al. [4] found a relative risk for coronary heart disease of 1.32 for an increase in serum Hcy of 4 μmol/l. A meta-analysis of 27 studies relating Hcy to coronary, cerebrovascular and peripheral arterial vascular diseases showed a very strong relationship between these diseases and tHcy [5]. More recently, a meta-analysis that examined 30 prospective and retrospective studies confirmed that increased plasma Hcy is an independent predictor of ischaemic heart disease although of moderate strength [6]. There are certain situations in which the risk posed by HHcy may be appreciably elevated. One of these is diabetes mellitus. There is evidence that HHcy is a stronger risk factor in patients with Type 2 diabetes [7,8] and in patients with existing coronary disease [9]. It is important, therefore, to understand the origin and metabolism of Hcy as well as the ways in which this is modified in diabetes.

Medicine